Literature DB >> 6156326

Effects of clofibrate, cholestyramine, zanchol, probucol, and AOMA feeding on hepatic and intestinal cholesterol metabolism and on biliary lipid secretion in the rat.

S D Turley, J M Dietschy.   

Abstract

Utilizing newer techniques for measuring rates of cholesterol synthesis, the effects of clofibrate, cholestyramine, zanchol, probucol, and AOMA (a copolymer of maleic acid and an alpha-olefin chain of 18 carbons) on hepatic and intestinal cholesterol metabolism and on biliary lipid secretion in the rat were examined. Uncer conditions of isocaloric feeding, female rats were administered a fixed amount of these drugs each day for 14 days. In one set of experiments the rats were killed and rates of hepatic and intestinal cholesterol synthesis and tissue cholesterol levels were measured. In a second set of studies the rats were subjected to total biliary diversion for 2 hr and rates of biliary lipid secretion were determined. Plasma cholesterol concentrations were measured in all animals. Neither AOMA nor cholestyramine had any effect on plasma cholesterol levels or biliary lipid secretion, but both markedly enhanced intestinal cholesterol synthesis. Cholestyramine also increased hepatic cholesterol synthesis. Clofibrate significantly decreased plasma cholesterol levels, whereas zanchol had the opposite effect. Both clofibrate and zanchol increased liver size and bile secretion rates but lowered biliary lipid concentrations; however, total biliary lipid output was unchanged. Total hepatic cholesterol synthesis in clofibrate-fed animals was similar to that in the controls, but in zanchol-fed animals it was approximately doubled. Neither clofibrate nor zanchol had any effect on intestinal cholesterol synthesis. Probucol dramatically lowered plasma cholesterol levels but had no effect on the other parameters measured. None of the drugs was effective in altering the molar percentage of cholesterol in bile despite the diversity of metabolic changes which occurred. These studies point up the many diverse metabolic effects of these drugs, some of which are clinically useful in lowering plasma cholesterol levels, and delineate the marked dissociations that occur between rates of cholesterol synthesis, tissue cholesterol levels, and plasma cholesterol concentrations.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6156326     DOI: 10.1097/00005344-198005000-00006

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Medical aspects of gallstones--1985: sixty years on.

Authors:  R H Dowling; D Gleeson
Journal:  Postgrad Med J       Date:  1985-10       Impact factor: 2.401

Review 2.  Effects of bezafibrate on hepatic cholesterol metabolism.

Authors:  D Ståhlberg; E Reihnér; S Ewerth; K Einarsson; B Angelin
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Effect of cholestyramine on bile acid metabolism in conventional rats.

Authors:  Y Imai; S Kawata; M Inada; S Miyoshi; Y Minami; Y Matsuzawa; K Uchida; S Tarui
Journal:  Lipids       Date:  1987-07       Impact factor: 1.880

4.  The role of Niemann-Pick C1 - Like 1 (NPC1L1) in intestinal sterol absorption.

Authors:  Stephen D Turley
Journal:  J Clin Lipidol       Date:  2008-04       Impact factor: 4.766

5.  Lipid accumulation in jejunal and colonic mucosa following chronic cholestyramine (Questran) feeding.

Authors:  M M Cassidy; F G Lightfoot; L Grau; S Satchitanandum; G V Vahouny
Journal:  Dig Dis Sci       Date:  1985-05       Impact factor: 3.199

6.  Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse.

Authors:  J Chianale; V Vollrath; A M Wielandt; L Amigo; A Rigotti; F Nervi; S Gonzalez; L Andrade; M Pizarro; L Accatino
Journal:  Biochem J       Date:  1996-03-15       Impact factor: 3.857

7.  The effects of clofibrate and bezafibrate on cholesterol metabolism in the liver of the male rat.

Authors:  J H Shand; D W West
Journal:  Lipids       Date:  1994-11       Impact factor: 1.880

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.